Phase IIi HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV
Vaccari, M.; Poonam, P.; Franchini, G.
Expert Review of Vaccines 9(9): 997-1005
2010
ISSN/ISBN: 1744-8395 PMID: 20822342 DOI: 10.1586/erv.10.104Document Number: 212452
The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
Document emailed within 0-6 h
Related Documents
Pérez-Losada, M.; Jobes, D.V.; Sinangil, F.; Crandall, K.A.; Arenas, M.; Posada, D.; Berman, P.W. 2011: Phylodynamics of HIV-1 from a phase IIi AIDS vaccine trial in Bangkok, Thailand PLOS one 6(3): E16902Thapinta, D.; Jenkins, R.A.; Morgan, P.A.; Chiu, J.; Boenim, W.; Bussaratid, V.; Chaddic, C.; Naksrisook, S.; Phonrat, B.; Sirijongdee, N.; Sornsathapornkul, P.; Sontirat, A.; Srisaengchai, P.; Suwanarach, C.; Wongkamhaeng, S.; Brown, A.E.; Khamboonruang, C.; Nitayaphan, S.; Pitisuttithum, P.; Thongchareon, P. 2002: Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand Journal of Acquired Immune Deficiency Syndromes 30(5): 503-513
Pitisuttithum, P.; Choopanya, K.; Bussaratid, V.; Vanichseni, S.; van Griensven, F.; Phonrat, B.; Martin, M.; Vimutsunthorn, E.; Sangkum, U.; Kitayaporn, D.; Tappero, J.W.; Heyward, W.; Francis, D. 2007: Social harms in injecting drug users participating in the first phase IIi HIV vaccine trial in Thailand Journal of the Medical Association of Thailand 90(11): 2442-2448
Rerks-Ngarm, S.; Premsri, N.; Namwat, C.; Khamboonruang, C.; Kunasol, P.; Pitisuttithum, P.; Kaewkungwal, J.; Nitayaphan, S.; Eamsila, C.; Benenson, M.W.; Paris, R.; Kim, J.H.; Rerks-Ngarm, S.; Chunsuttiwat, S.; Premsri, N.; Namwat, C.; Kunasol, P.; Thongcharoen, P.; Khamboonruang, C.; Pitisuttithum, P.; Bussaratid, V.; Maek-a-nantawat, W.; Dhitavat, J.; Suntharasamai, P.; Pungpak, S.; Vanijanonta, S.; Kaewkungwal, J.; Khamsiriwatchara, A.; Jarujareet, P.; Nitayaphan, S.; Easmila, C.; Tabprasit, S.; Paris, R.; Benenson, M.; Morgan, P. 2011: Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148) Vaccine 29(25): 4285-4292
Nosten, F.; Luxemburger, C.; Kyle, D.E.; Ballou, W.R.; Wittes, J.; Wah, E.; Chongsuphajaisiddhi, T.; Gordon, D.M.; White, N.J.; Sadoff, J.C.; Heppner, D.G. 1996: Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group Lancet 348(9029): 701-707
Wheeler, C.M.; Castellsagué, X.; Garland, S.M.; Szarewski, A.; Paavonen, J.; Naud, P.; Salmerón, J.; Chow, S.-N.; Apter, D.; Kitchener, H.; Teixeira, J.úl.C.; Skinner, S.R.; Jaisamrarn, U.; Limson, G.; Romanowski, B.; Aoki, F.Y.; Schwarz, T.F.; Poppe, W.A.J.; Bosch, F.X.; Harper, D.M.; Huh, W.; Hardt, K.; Zahaf, T.; Descamps, D.; Struyf, F.; Dubin, G.; Lehtinen, M.; Denham, I.; Garland, S.M.; Mindel, A.; O'Sullivan, M.; Skinner, S.R.; Waddell, R.; De Sutter, P.; Poppe, W.A.J.; Tjalma, W.; De Carvalho, N.S.; Naud, P.; Teixeira, J.C.; Aoki, F.Y.; Diaz-Mitoma, F.; Dionne, M.; Ferguson, L.; Miller, M.; Papp, K.; Ramjattan, B.; Romanowski, B.; Somani, R.; Apter, D.; Karppa, T.; Kudjoi, N.; Kyha-österlund, L.; Lehtinen, M.; Levanen, H.; Lönn 2012: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial LANCET. Oncology 13(1): 100-110
Bakari, M.; Munseri, P.; Francis, J.; Aris, E.; Moshiro, C.; Siyame, D.; Janabi, M.; Ngatoluwa, M.; Aboud, S.; Lyamuya, E.; Sandström, E.; Mhalu, F. 2013: Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/Ii HIVIS 03 trial Bmc Public Health 13: 1149
Wilhelmson, B. 1993: Trial and error for pertussis vaccine. Does the new recombinant vaccine have superior qualities? Lakartidningen 90(26-27): 2458-2459
Andrasik, M.P.; Sesay, F.Albertina.; Isaacs, A.; Oseso, L.; Allen, M. 2020: Social Impacts among Participants in HIV Vaccine Trial Network (HVTN) preventive HIV vaccine trials Journal of Acquired Immune Deficiency Syndromes 2020
Schmitt-Grohé, S.; Stehr, K.; Cherry, J.D.; Heininger, U.; Uberall, M.A.; Laussucq, S.; Eckhardt, T. 1997: Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group Developments in Biological Standardization 89: 113-118
Jenkins, R.A.; Thapinta, D.; Morgan, P.A.; Wongkamhaeng, S.; Sornsathapornkul, P.; Bussaratid, V.; Sontirat, A.; Pitisuttithum, P.; Thongchareoen, P.; Khamboonruang, C.; Suriyanon, V.; Nitayaphan, S.; Brown, A.E. 2005: Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand Journal of Acquired Immune Deficiency Syndromes 40(5): 592-599
Agnandji, S.Todagbe.; Lell, B.; Soulanoudjingar, S.Solmeheim.; Fernandes, Jé.Francisco.; Abossolo, Béatrice.Peggy.; Conzelmann, C.; Methogo, B.Gaelle.Nfono.Ondo.; Doucka, Y.; Flamen, A.; Mordmüller, B.; Issifou, S.; Kremsner, P.Gottfried.; Sacarlal, J.; Aide, P.; Lanaspa, M.; Aponte, J.J.; Nhamuave, A.; Quelhas, D.; Bassat, Q.; Mandjate, S.; Macete, Eébio.; Alonso, P.; Abdulla, S.; Salim, N.; Juma, O.; Shomari, M.; Shubis, K.; Machera, F.; Hamad, A.Said.; Minja, R.; Mtoro, A.; Sykes, A.; Ahmed, S.; Urassa, A.Martin.; Ali, A.Mohammed.; Mwangoka, G.; Tanner, M.; Tinto, H 2011: First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children New England Journal of Medicine 365(20): 1863-1875
Tarimo, E.A.M.; Thorson, A.; Kohi, T.W.; Bakari, M.; Sandstrom, E.; Mhalu, F.; Kulane, A. 2011: A qualitative evaluation of volunteers' experiences in a phase I/Ii HIV vaccine trial in Tanzania Bmc Infectious Diseases 11: 283
Chintu, C.; Gupta, K.; Osborne, C.; Masona, J.M. 1983: Clinical trial of the protective role of polyvalent pneumococcal vaccine in sickle cell anaemia patients in Zambia Medical Journal of Zambia 17(3): 73-76
Jones, W.R.; Bradley, J.; Judd, S.J.; Denholm, E.H.; Ing, R.M.; Mueller, U.W.; Powell, J.; Griffin, P.D.; Stevens, V.C. 1988: Phase i clinical trial of a World Health Organisation birth control vaccine Lancet 1(8598): 1295-1298
Newman, P.A.; Roungprakhon, S.; Tepjan, S.; Yim, S.; Walisser, R. 2012: A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand Global Public Health 7(9): 1009-1024
Vanichseni, S.; Tappero, J.W.; Pitisuttithum, P.; Kitayaporn, D.; Mastro, T.D.; Vimutisunthorn, E.; van Griensvan, F.; Heyward, W.L.; Francis, D.P.; Choopanya, K. 2004: Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand Aids 18(2): 311-316
Tarimo, E.A.M.; Thorson, A.; Kohi, T.W.; Bakari, M.; Mhalu, F.; Kulane, A. 2011: Reasons for declining to enroll in a phase i and Ii HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania Plos one 6(2): E14619
Kibuuka, H.; Guwatudde, D.; Kimutai, R.; Maganga, L.; Maboko, L.; Watyema, C.; Sawe, F.; Shaffer, D.; Matsiko, D.; Millard, M.; Michael, N.; Wabwire-Mangen, F.; Robb, M. 2009: Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa Plos one 4(4): E5164
Giocos, G.; Kagee, A.; Swartz, L. 2008: Predicting hypothetical willingness to participate (WTP) in a future phase IIi HIV vaccine trial among high-risk adolescents Aids and Behavior 12(6): 842-851